Evidence map›Paper›PMID 35298627›Full record

ArticleHuman molecular genetics2022

L1 chimeric transcripts are expressed in healthy brain and their deregulation in glioma follows that of their host locus.

Marie-Elisa Pinson, Franck Court, Aymeric Masson, Yoan Renaud, Allison Fantini, Ophélie Bacoeur-Ouzillou, Marie Barriere, Bruno Pereira, Pierre-Olivier Guichet, Emmanuel Chautard and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Human molecular genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Transposable Elements Co-Option in Genome Evolution and Gene Regulation.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Marie-Elisa PinsonUniversité Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France.
Franck CourtUniversité Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France.
Aymeric MassonUniversité Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France.
Yoan RenaudUniversité Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France.
Allison FantiniUniversité Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France.
Ophélie Bacoeur-OuzillouUniversité Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France.
Marie BarriereUniversité Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France.
Bruno PereiraBiostatistics Department, Délégation à la Recherche Clinique et à l'Innovation, Clermont-Ferrand Hospital, Clermont-Ferrand 63003, France.
Pierre-Olivier GuichetCancer Biology Department, CHU de Poitiers, Poitiers 86021, France.
Emmanuel ChautardUniversité Clermont Auvergne, INSERM, U1240 IMoST, Clermont-Ferrand 63011, France.
Lucie Karayan-TaponCancer Biology Department, CHU de Poitiers, Poitiers 86021, France.
Pierre VerrelleINSERM, U1196 CNRS UMR9187, Curie Institute, Orsay 91405, France.
Philippe ArnaudUniversité Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France.ORCID 0000-0002-7937-8764
Catherine Vaurs-BarrièreUniversité Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France.ORCID 0000-0001-8654-4292
Centre National de la Recherche Scientifique · FRInserm · FRCentre Hospitalier Universitaire de Poitiers · FRInstitut Génétique, Reproduction et Développement · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Besides the consequences of retrotransposition, long interspersed element 1 (L1) retrotransposons can affect the host genome through their antisense promoter. In addition to the sense promoter, the evolutionarily recent L1 retrotransposons, which are present in several thousand copies, also possess an anti-sense promoter that can produce L1 chimeric transcripts (LCT) composed of the L1 5' UTR followed by the adjacent genomic sequence. The full extent to which LCT expression occurs in a given tissue and whether disruption of the defense mechanisms that normally control L1 retrotransposons affects their expression and function in cancer cells, remain to be established. By using CLIFinder, a dedicated bioinformatics tool, we found that LCT expression was widespread in normal brain and aggressive glioma samples, and that approximately 17% of recent L1 retrotransposons, from the L1PA1 to L1PA7 subfamilies, were involved in their production. Importantly, the transcriptional activities of the L1 antisense promoters and of their host loci were coupled. Accordingly, we detected LCT-producing L1 retrotransposons mainly in transcriptionally active genes and genomic loci. Moreover, changes in the host genomic locus expression level in glioma were associated with a similar change in LCT expression level, regardless of the L1 promoter methylation status. Our findings support a model in which the host genomic locus transcriptional activity is the main driving force of LCT expression. We hypothesize that this model is more applicable when host gene and LCT are transcribed from the same strand.

Indexed as

GliomaRetroelementsBrainHumansLong Interspersed Nucleotide ElementsPromoter Regions, GeneticRetroelements

Identifiers

PMID35298627
PMCPMC9396940
OpenAlexW4220791274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.